natgillin/translations-raw huggingface dataset:
Work on the mat provided and wash your hands before performing the following procedures. 
Delo opravite na priloženi zaščitni podlogi, pred opravljanjem naslednjih postopkov si umijte roke.
No genotoxicity studies were performed as the active substance is unlikely to interact directly with DNA or other chromosomal material. 
Študije genotoksičnosti niso bile opravljene, ker ni verjetno, da bi zdravilna učinkovina vzajemno delovala neposredno z DNK ali drugim kromosomskim materialom.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Cinryze. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
• When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. 
• Kadar so zdravila izdelana iz humane krvi ali plazme, se uporabljajo nekateri ukrepi, ki preprečujejo, da bi se okužbe prenašale na bolnike.
The continued need for regular prophylaxis with Cinryze should be reviewed on a regular basis. 
Stalno potrebo po redni profilaksi z zdravilom Cinryze morate redno preverjati.
If you have a low amount of C1 inhibitor in your blood or your C1 inhibitor is not working properly, this can lead to swelling attacks (called angioedema). 
Če imate nizko koncentracijo zaviralca C1 v krvi ali če zaviralec C1 pri vas ne deluje pravilno, se lahko pojavljajo napadi otekanja (ki se imenujejo angioedem).
Overall, the safety and tolerability of Cinryze are similar in children, adolescents and adults. 
V celoti gledano sta varnost in prenašanje zdravila Cinryze pri otrocih, mladostnikih in odraslih podobna.
Functional C1 inhibitor activity was measured in children in the two open label studies (see section 5.1). 
Aktivnost funkcionalnega zaviralca C1 so merili pri otrocih v dveh odprtih študijah (glejte poglavje 5.1).
6 to 11 years: 
Od 6 do 11 let:
PSUR Cycle 
Cikel PSUR
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Cinryze therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Cinryze, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
No case of overdose has been reported. 
Poročali niso o nobenem primeru prevelikega odmerjanja.
C1 inhibitor is a naturally occurring protein that is normally present in the blood. 
Zaviralec C1 je naravna beljakovina, ki je normalno prisotna v krvi.
For 98% of procedures, no HAE attacks were reported within the 72 hours after the Cinryze dose. 
Pri 98 % posegov niso poročali o nobenem napadu HAE znotraj 72 ur po odmerku zdravila Cinryze.
Age-Group 6-11 years: 
Starostna skupina 6-11 let:
The total protein content of the reconstituted solution is 15 ± 5 mg/ml. 
Celotna vsebnost beljakovin rekonstituirane raztopine je 15 ± 5 mg/ml.
Pharmacotherapeutic group: Drugs used in hereditary angioedema, C1 inhibitor, plasma derived, ATC code: B06AC01. 
Farmakoterapevtska skupina: zdravila, ki se uporabljajo za dedni angioedem, zaviralci C1, izpeljani iz plazme, oznaka ATC: B06AC01.
Manufacturers of these products also include steps in the processing of the blood or plasma that can inactivate or remove viruses. 
Izdelovalci teh izdelkov pri predelavi krvi in plazme uporabljajo tudi ukrepe, ki lahko inaktivirajo ali odstranijo viruse.
2 to 11 years, >25 kg: 
Od 2 do 11 let, > 25 kg:
This also applies to any unknown or emerging viruses or other types of infections. 
To velja tudi za morebitne neznane oziroma nove viruse ali druge vrste okužb.
Use either the filter transfer device provided with Cinryze or a commercially available double-ended needle. 
Uporabite bodisi pripravo za prenos s filtrom, ki je priložena zdravilu Cinryze, bodisi iglo z dvema koncema, ki je komercialno na voljo.
Cinryze is not for use in children below 6 years of age for routine prevention of angioedema attacks. 
Zdravilo Cinryze ni namenjeno uporabi pri otrocih, mlajših od 6 let, za rutinsko preprečevanje napadov angioedema.
No studies on fertility, early embryonic and post-natal development, or carcinogenicity studies were conducted because chronic dosing in animals would be expected to be associated with development of neutralising antibodies to the human protein. 
Študije plodnosti, zgodnjega razvoja zarodka in ploda ter študije kancerogenosti niso bile opravljene, ker je pričakovati, da bo kronično odmerjanje živalim povezano z razvojem nevtralizirajočih protiteles proti humani beljakovini.
Educational materials for non-healthcare professionals 
Izobraževalna gradiva za osebe, ki niso zdravstveni delavci.
Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). 
Zdravljenje in predoperativno preprečevanje napadov angioedema pri odraslih, mladostnikih in otrocih (starih 2 leti in več) z dednim angioedemom (HAE-hereditary angioedema).
In clinical studies local reactions (described as pain, bruising, or rash at the injection/catheter site, venous burning or phlebitis) occurred in association with approximately 0.2% of infusions. 
V kliničnih študijah so se lokalne reakcije (opisane kot bolečina, modrica ali izpuščaj na mestu injiciranja/katetra, občutek pečenja v veni ali flebitis) pojavile v povezavi s približno 0,2 % infuzij.
Adverse reactions reported in clinical studies and in postmarketing reports 
Neželeni učinki, o katerih so poročali v kliničnih študijah in v poročilih v obdobju trženja Organski sistem
What you need to know before you take Cinryze 
Kaj morate vedeti, preden boste vzeli zdravilo Cinryze
There is limited information on the safety of Cinryze use during pregnancy and breast-feeding. 
Podatkov o varnosti uporabe zdravila Cinryze med nosečnostjo in dojenjem je malo.
The recommended dose of Cinryze for adults, adolescents, children, the elderly, or patients suffering from kidney or liver problems is as follows: 
Priporočeni odmerek zdravila Cinryze za odrasle, mladostnike, otroke, starejše bolnike in bolnike, ki imajo težave z ledvicami ali jetri, je:
After it has been dissolved in the water for injections the solution is clear and colourless to slightly blue. 
Potem ko se prašek raztopi v vodi za injekcije, je raztopina bistra in brezbarvna do rahlo modra.
It is unknown whether C1 inhibitor is excreted in human milk. 
Ni znano, ali se zaviralec C1 izloča v materino mleko.
The dosing interval and dose may need to be adjusted according to individual response. 
Presledek med odmerki in odmerek po potrebi prilagodite odzivu posameznika.
Gently swirl the powder vial until all powder is dissolved. 
Nežno sukajte vialo s praškom, dokler se ne raztopi ves prašek.
Tell your doctor immediately if you experience any of the following symptoms after taking this medicine. 
Nemudoma povejte zdravniku, če po uporabi tega zdravila opazite enega ali več od naslednjih simptomov.
2 to 11 years, 10-25 kg: 
Od 2 do 11 let, 10-25 kg:
Potential risks associated with home-treatment are related to the administration itself as well as the handling of adverse reactions, particularly hypersensitivity. 
Možne nevarnosti, povezane z zdravljenjem na domu, so povezane s samo uporabo zdravila, pa tudi z ukrepanjem pri neželenih učinkih, posebno pri preobčutljivosti.
For subjects with >1 attack, the proportion of attacks responding within 4 hours after Cinryze dosing and the time to response was comparable regardless of the number of attacks treated. 
Pri preiskovancih z več kot enim napadom sta bila delež napadov, ki so se odzvali v štirih urah po odmerku zdravila Cinryze, in čas do odziva primerljiva ne glede na število zdravljenih napadov.
The very common adverse reactions observed following Cinryze infusion in clinical studies were headache and nausea. 
Zelo pogosta neželena učinka, ki so ju opazili po infuziji zdravila Cinryze v kliničnih študijah, sta bila glavobol in navzea.
The decision on the use of home- treatment for an individual patient should be made by the treating physician, who should ensure that appropriate training is provided and the use reviewed at intervals. 
Odločitev o uporabi zdravljenja posameznega bolnika na domu mora sprejeti lečeči zdravnik, ki mora zagotoviti, da je na voljo ustrezno izobraževanje in da se uporaba ocenjuje v rednih presledkih.
Do not use Cinryze after the expiry date which is stated on the carton or vials after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli ali vialah poleg oznake “EXP”.
You will be required to keep a diary in order to document each treatment received at home and to bring it to each of your visits to the doctor. 
Voditi boste morali dnevnik, da boste dokumentirali vsak doma prejeti odmerek zdravila, in ga pri vsakem obisku prinesti zdravniku.
Study LEVP 2006-1: Twenty-two paediatric subjects were treated for 121 acute HAE attacks. 
Študija LEVP 2006-1: Dvaindvajset pediatričnih preiskovancev se je zdravilo zaradi 121 akutnih napadov HAE.
Regular review of the administration by the patient/carer needs to be performed to ensure maintenance of optimal practice. 
Treba je redno ocenjevati bolnikovo/negovalčevo uporabo zdravila, da se zagotovi vzdrževanje najboljše prakse.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. 
Standardni ukrepi za preprečevanje infekcij, ki nastanejo zaradi uporabe zdravil, pripravljenih iz humane krvi ali plazme, vključujejo izbiro dajalcev, presejalno testiranje krvi posameznih dajalcev in zalog plazme na specifične označevalce okužb in vključitev učinkovitih izdelavnih standardov za inaktivacijo/odstranitev virusov.
Across clinical studies, there were 61 unique paediatric subjects enrolled and exposed to over 2,500 infusions of Cinryze (2-5 years, n=3; 6-11 years, n=32; 12-17 years, n=26). 
V klinične študije je bilo vključenih 61 različnih pediatričnih bolnikov, ki so bili izpostavljeni več kot 2500 infuzijam zdravila Cinryze (2-5 let, n=3; 6-11 let, n=32; 12-17 let, n=26).
For safety with respect to transmissible agents, see section 4.4. 
Za varnost v zvezi s prenosljivimi povzročitelji bolezni glejte poglavje 4.4.
Data from two randomised, double-blind, placebo-controlled studies (LEVP 2005-1/A and LEVP 2005-1/B), data from two open-label studies (LEVP 2006-1 and LEVP 2006-4) and 2 paediatric clinical studies (0624-203 and 0624-301) demonstrated the efficacy of Cinryze for the treatment and prevention of angioedema attacks in subjects with HAE. 
Podatki iz dveh randomiziranih, dvojno slepih, s placebom kontroliranih študij (LEVP 2005-1/A in LEVP 2005-1/B), podatki iz dveh odprtih študij (LEVP 2006-1 in LEVP 2006-4) in 2 pediatričnih kliničnih študij (0624-203 in 0624-301) so pokazali učinkovitost zdravila Cinryze za zdravljenje in preprečevanje napadov angioedema pri osebah s HAE.
Sudden wheeziness, difficulty in breathing, swelling of eyelids, face or lips, rash or itching (especially affecting the whole body). 
Nenadna zasoplost, oteženo dihanje, otekanje vek, obraza ali ustnic, izpuščaj ali srbenje (posebno po vsem telesu).
Only frequencies based on reporting rates from clinical trials are used to assign frequency category. 
Za dodelitev v kategorijo pogostnosti so uporabili le pogostnosti na podlagi stopenj poročanja iz kliničnih preskušanj.
Store the remaining vial and administration equipments for the next dose. 
Preostalo vialo in pripomočke za dajanje zdravila shranite za naslednji odmerek.
Adverse reaction frequencies were estimated from 2 pivotal placebo-controlled and 2 open-label studies in 251 unique subjects. 
Pogostnosti neželenih učinkov so ocenili na podlagi 2 osrednjih, s placebom nadzorovanih, in 2 odprtih študijah pri 251 edinstvenih osebah.
Very common side effects (may affect more than 1 in 10 people): headache, nausea. 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): glavobol, navzea.
Using the same syringe, repeat steps 3 to 6 with a second vial of reconstituted Cinryze to make one complete 10 ml dose. 
Z isto brizgo ponovite korake 3 do 6 z drugo vialo rekonstituiranega zdravila Cinryze, da boste dobili kompleten 10-mililitrski odmerek.
• Additional risk minimisation measures Prior to launch of the product in each Member State, the Marketing Authorisation Holder shall agree the content and format of the educational material with the national competent authority. 
Pred uvedbo zdravila na trg v vsaki državi članici mora imetnik dovoljenja za promet z zdravilom uskladiti vsebino in obliko izobraževalnega gradiva z nacionalnim pristojnim organom.
Each pack of Cinryze contains: 
Eno pakiranje zdravila Cinryze vsebuje:
Note: the transfer device must be attached to the solvent vial before being attached to the powder vial, so that the vacuum in the powder vial is not lost. 
Opozorilo: pripravo za prenos morate pritrditi na vialo z vehiklom, preden jo pritrdite na vialo s praškom, da se ne izgubi vakuum v viali s praškom.
Within 4 hours after Cinryze dosing, 87% of attacks achieved unequivocal relief of the defining symptom. 
V štirih urah po odmerku zdravila Cinryze je pri 87 % napadov nastopilo nedvomno olajšanje opredeljujočega simptoma.
As such, the pharmacokinetics and excretion of Cinryze are not expected to be altered by renal or hepatic impairment. 
Zato ne pričakujemo, da bi se farmakokinetika in izločanje zdravila Cinryze spremenila zaradi okvare ledvic ali jeter.
2 protective mats 
2 zaščitni podlogi.
Median interval was 0.5 hours (range: 0.25-2.5 hours): 1.25, 0.25, and 0.5 hours in the 500 Units(), 1000 Units(), and 1500 Units() Cinryze groups, respectively. 
Mediani interval je bil 0,5 ure (razpon: 0,25-2,5 ure): 1,25, 0,25 in 0,5 ure pri 500 enotah
C1 inhibitor is a single chain glycoprotein found in plasma which, in its mature state, consists of 478 amino acids with an apparent molecular weight of 105 kD. 
Zaviralec C1 je glikoprotein iz ene same verige, najdemo ga v plazmi, v svojem zrelem stanju pa je sestavljen iz 478 aminokislin z navidezno molekulsko maso 105 kD.
Cleanse stoppers with a disinfection swab and allow them to dry prior to use. 
Obrišite zamaška z zložencem za dezinfekcijo in ju pustite, da se pred uporabo posušita.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19. 
Izvedeni ukrepi veljajo za učinkovite za viruse z ovojnico, na primer HIV, HBV in HCV, in za gola virusa HAV in parvovirus B19.
Necessary skills have to be acquired by non-healthcare professionals before Cinryze may be safely and effectively administered at home. 
Osebe, ki niso zdravstveni delavci, si morajo pridobiti potrebno znanje, preden se lahko zdravilo Cinryze varno in učinkovito uporabljajo doma.
These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/infections. 
Med temi ukrepi sta skrbna izbira dajalcev krvi in plazme, ki zagotavlja, da sta izključeni kri in plazma tveganih dajalcev, s katerima bi se lahko prenašale okužbe, in testiranje vsake enote darovane krvi posameznih dajalcev in zalog plazme na znake virusov/okužb.
Because C1 inhibitor is an endogenous human plasma protein, it is not subject to metabolism by Cytochrome P450 iso-enzymes, excretion, or pharmacokinetic drug-drug interactions exhibited by many low molecular weight compounds. 
Ker je zaviralec C1 endogena humana plazemska beljakovina, ni izpostavljen presnavljanju z izoencimi citokroma P450, izločanju ali farmakokinetičnim interakcijam med zdravili, kot so številne spojine z majhno molekulsko maso.
Do not reuse the transfer device. 
Ne uporabite še enkrat že uporabljene priprave za prenos.
In all studies, administration of Cinryze resulted in increases in antigenic and functional C1 inhibitor levels post-infusion compared to pre-infusion values in both children and adults. 
V vseh študijah je uporaba zdravila Cinryze zvečala ravni antigenskega in funkcionalnega inhibitorja C1 po infuzijah v primerjavi z vrednostmi pred infuzijami pri otrocih in odraslih.
Mean increases from baseline in functional C1 inhibitor activity measured 1 hour post-dose in children 2 to <18 years of age ranged from 20% to 88% in Study LEVP 2006-1 (treatment) and from 22% to 46% in Study LEVP 2006-4 (prevention) compared with 21% to 66% and 25% to 32% in adults, respectively. 
Povprečno zvečanje aktivnosti funkcionalnega zaviralca C1 od izhodišča, izmerjeno 1 uro po odmerku pri otrocih, starih 2 do <18 let, je bilo med 20 % in 88 % v študiji LEVP 2006-1 (zdravljenje) in med 22 % in 46 % v študiji LEVP 2006-4 (preprečevanje) v primerjavi z 21 % do 66 % in 25 % do 32% pri odraslih.
Home-treatment and self-administration 
Zdravljenje na domu in samozdravljenje
The mean elimination half-life of functional C1 inhibitor after administration of Cinryze was 56 hours for a single dose and 62 hours for the double dose. 
Povprečni razpolovni čas odstranjevanja funkcionalnega zaviralca C1 iz telesa po aplikaciji zdravila Cinryze je bil 56 ur pri enkratnem odmerku in 62 ur pri dvojnem odmerku.
Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. 
Bolnike moramo poučiti o začetnih znakih preobčutljivostnih reakcij, vključno s koprivnico, generalizirano urtikarijo, stiskanjem v prsih, sopenjem, hipotenzijo in anafilaksijo.
Cinryze vial is for single use only. 
Viala zdravila Cinryze je samo za enkratno uporabo.
The educational material for healthcare professionals should include information on the following key elements: 
Izobraževalno gradivo za zdravstvene delavce mora vključevati informacije o naslednjih ključnih elementih:
Among 15 subjects treated with open-label Cinryze for laryngeal HAE attacks, none required intubation. 
Pri nobenem od 15 preiskovancev, zdravljenih z odprtim zdravilom Cinryze za laringealne napade HAE, ni bila potrebna intubacija.
Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. 
Rutinsko preprečevanje napadov angioedema pri odraslih, mladostnikih in otrocih (starih 6 let in več) s hudimi in ponavljajočimi se napadi dednega angioedema (HAE), ki ne prenašajo peroralnih zdravil za preprečevanje ali jih ta zdravila ne zaščitijo dovolj, ali pri bolnikih, pri katerih ponavljajoče se akutno zdravljenje ne zadostuje.
The expected consequence of metabolism of a glycoprotein is via degradation to small peptides and individual amino acids. 
Za glikoprotein pričakujemo, da se presnavlja z degradacijo v majhne peptide in posamezne aminokisline.
Based upon an animal study there is a potential thrombogenic threshold at doses greater than 200 Units 
Sodeč po študiji na živalih je možen trombogeni prag pri odmerkih nad 200 enot(*)/kg.
As with any biological product hypersensitivity reactions may occur. 
Podobno kot pri drugih bioloških zdravilih lahko nastopijo preobčutljivostne reakcije.
Mean Pharmacokinetic Parameters for Functional C1 Inhibitor Following Administration of Cinryze 
Povprečni farmakokinetični parametri za funkcionalni zaviralec C1 po uporabi zdravila Cinryze
In adults and children, Cinryze can raise the amount of C1 inhibitor in the blood and either prevent (prior to undergoing medical or dental procedures) these swelling attacks from occurring or stop swelling attacks once they have begun. 
Pri odraslih in otrocih lahko zdravilo Cinryze zviša koncentracijo zaviralca C1 v krvi in bodisi prepreči (pred medicinskimi ali zobozdravstvenimi posegi), da bi se ti napadi otekanja pojavljali, bodisi tak napad zaustavi, če se je že začel.
Do not remove the device from the package. 
Ne vzemite priprave iz pakiranja.
Because these pathways are part of enzyme amplification cascades, without C1 inhibitor, spontaneous or trigger-induced activation of these pathways can lead to unopposed activation and swelling. 
Ker so te presnovne poti del encimskih ojačevalnih kaskad, lahko spontana ali s sprožilcem povzročena aktivacija teh presnovnih poti brez zaviralca C1 povzroči neovirano aktivacijo in otekanje.
You or your carer might also administer Cinryze as an injection, but only after receiving adequate training. 
Zdravilo Cinryze si lahko injicirate tudi sami ali vam ga injicira vaš negovalec, vendar le po tem, ko se ustrezno izobrazita.
Each product vial should be reconstituted with 5 ml water for injections. 
Vsako vialo z zdravilom rekonstituirajte s 5 ml vode za injekcije.
Cinryze for the pre-procedure prevention of HAE attacks Open-label Cinryze was administered within 24 hours prior to a total of 91 medical, dental, or surgical procedures across the clinical programme (40 procedures in children and 51 procedures in adults). 
Zdravilo Cinryze za preoperativno preprečevanje napadov HAE Odprto zdravilo Cinryze so uporabili največ 24 ur pred vsega skupaj 91 medicinskimi, stomatološkimi ali operativnimi posegi v spektru kliničnega programa (40 posegov pri otrocih in 51 posegov pri odraslih).
The educational material for non-healthcare professionals should include information on the following key elements: 
Izobraževalno gradivo za osebe, ki niso zdravstveni delavci, naj obsega informacije o naslednjih ključnih elementih:
C1 inhibitor inhibits the complement system by binding C1r and C1s, two of the active enzyme subunits of the first component of the complement system (C1) in the classical pathway, as well as to mannose-binding lectin-associated serine proteases in the lectin pathway. 
Zaviralec C1 zavira sistem komplementa, tako da veže C1r in C1s, dve od aktivnih encimskih podenot prve komponente sistema komplementa (C1) v klasični presnovni poti, pa tudi z lektinom povezane serinske proteaze, ki vežejo manozo, v lektinski presnovni poti.
If your doctor decides you can selfadminister, your doctor or nurse will train you or a family member to prepare and inject Cinryze. 
Če se bo zdravnik odločil, da si lahko zdravilo dajete sami, bo on ali medicinska sestra naučil vas ali vašega družinskega člana pripravljati in injicirati zdravilo Cinryze.
Regular review of your/your carer's injection technique will be performed to ensure continued appropriate handling. 
Zdravnik bo tudi redno ocenjeval vašo tehniko injiciranja oziroma tehniko injiciranja vašega negovalca, da bo zagotovljeno stalno ustrezno ravnanje z zdravilom.
Each vial of Cinryze contains approximately 11.5 mg of sodium. 
Ena viala zdravila Cinryze vsebuje približno 11,5 mg natrija.
Ensure the powder vial and the solvent vial are at room temperature (15ºC - 25ºC). 
Poskrbite, da bosta viala s praškom in viala z vehiklom segreti na sobno temperaturo (15 ºC - 25 ºC).
• Cinryze should be injected intravenously (into the vein). 
• Zdravilo Cinryze se mora injicirati intravensko (v veno).
Your treatment will be initiated and managed under supervision of a doctor experienced in the care of patients with hereditary angioedema (HAE). 
Vaše zdravljenje bo začel, vodil in nadzoroval zdravnik, ki ima izkušnje z zdravljenjem bolnikov z dednim angioedemom (HAE - hereditary angioedema).
• For patients experiencing laryngeal attacks or if initiation of treatment is delayed, the second dose can be given sooner than 60 minutes. 
• Pri bolnikih, ki imajo laringealne napade, in v primerih, ko je zdravljenje uvedeno z zamudo, smemo dati drugi odmerek prej kot po 60 minutah.
Other medicines and Cinryze 
Druga zdravila in zdravilo Cinryze
Double Dose (1000 Units dose followed by a second 1000 Units dose 60 minutes later) 
Dvojni odmerek (odmerek 1000 enot, čez 60 minut še en odmerek 1000 enot)